FHL-2 Inhibitors
The class of FHL-2 inhibitors comprises a set of diverse chemicals that modulate the function of FHL-2, a protein involved in various cellular processes. These inhibitors either directly target FHL-2 or act indirectly by influencing specific signaling pathways associated with FHL-2. Galunisertib, SB431542, LY364947, SB525334, RepSox, and SD-208 are inhibitors of the transforming growth factor-beta (TGF-β) pathway by selectively targeting the TGF-β type I receptor ALK5. FHL-2 is implicated in TGF-β signaling, and these inhibitors disrupt FHL-2-mediated TGF-β signaling, affecting cellular processes such as cell proliferation, migration, and differentiation. Pirfenidone is an anti-fibrotic drug that indirectly inhibits FHL-2 by modulating TGF-β production and activity. This inhibition impacts FHL-2 involvement in cellular processes related to fibrosis and tissue remodeling.
EW-7197 is another ALK5 inhibitor that disrupts FHL-2-mediated TGF-β signaling, providing a tool to investigate the specific impact of ALK5 inhibition on FHL-2 function and cellular dynamics. SB216763 and CHIR-99021 are inhibitors of glycogen synthase kinase 3 (GSK-3), which interacts with FHL-2. These inhibitors modulate FHL-2-mediated pathways, affecting cellular processes such as proliferation and apoptosis. XAV939 and IQ-1 are inhibitors of tankyrase, indirectly influencing FHL-2-mediated pathways associated with the Wnt signaling pathway. These inhibitors impact FHL-2 involvement in cellular processes related to Wnt signaling, such as cell proliferation, migration, and differentiation. This diverse set of inhibitors provides valuable tools for researchers to explore the intricate regulatory mechanisms of FHL-2 in various cellular processes. The specific targeting of FHL-2 or its associated pathways allows for detailed investigations into the role of FHL-2 in normal cellular physiology and disease states. Researchers can leverage these inhibitors to unravel the complexities of FHL-2 function and its implications for cellular dynamics.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $209.00 $352.00 | 3 | |
LY2157299 is a selective inhibitor of transforming growth factor-beta (TGF-β) receptor type I (ALK5). FHL-2 is involved in TGF-β signaling pathways, and Galunisertib inhibits ALK5, preventing downstream signaling. This inhibition interferes with FHL-2 modulation within the TGF-β pathway, affecting cellular processes regulated by FHL-2-mediated TGF-β signaling, such as cell proliferation and differentiation. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 is a selective inhibitor of TGF-β type I receptors, including ALK5. FHL-2 interacts with TGF-β signaling components, and SB431542 inhibits ALK5, disrupting FHL-2-mediated TGF-β signaling. This inhibition hampers FHL-2 involvement in cellular processes regulated by TGF-β, such as extracellular matrix production and tissue remodeling. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $105.00 $153.00 | 4 | |
LY364947 is a potent and selective inhibitor of TGF-β receptor type I (ALK5). FHL-2 is associated with TGF-β pathways, and LY364947 inhibits ALK5, interfering with FHL-2-mediated TGF-β signaling. This inhibition affects FHL-2 involvement in cellular processes regulated by TGF-β, such as cell migration and immune response modulation. LY364947 serves as a tool to investigate the specific impact of ALK5 inhibition on FHL-2 function and cellular dynamics. | ||||||
TGF-β RI Kinase Inhibitor VIII | 356559-20-1 | sc-203295 | 2 mg | $100.00 | 2 | |
FHL-2 participates in TGF-β signaling pathways, and TGF-β RI Kinase Inhibitor VIII inhibits ALK5, disrupting FHL-2-mediated TGF-β signaling. This inhibition interferes with FHL-2 involvement in cellular processes regulated by TGF-β, such as epithelial-mesenchymal transition and fibrosis. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $75.00 $150.00 $215.00 $650.00 $1224.00 $4296.00 $7818.00 | 8 | |
Rapamycin is a selective inhibitor of TGF-β type I receptors, including ALK5. FHL-2 is associated with TGF-β pathways, and RepSox inhibits ALK5, disrupting FHL-2-mediated TGF-β signaling. This inhibition interferes with FHL-2 involvement in cellular processes regulated by TGF-β, such as cell proliferation and apoptosis. | ||||||
Pirfenidone | 53179-13-8 | sc-203663 sc-203663A | 10 mg 50 mg | $100.00 $408.00 | 6 | |
Pirfenidone is an anti-fibrotic drug that inhibits TGF-β production and activity. FHL-2 is implicated in TGF-β signaling, and Pirfenidone modulates TGF-β levels, indirectly affecting FHL-2-mediated pathways. This inhibition influences FHL-2 involvement in cellular processes regulated by TGF-β, such as fibrosis and tissue remodeling. Pirfenidone provides a tool to explore the specific impact of TGF-β modulation on FHL-2 function and cellular dynamics. | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | $86.00 | 3 | |
FHL-2 interacts with TGF-β signaling components, and TGF-β RI Kinase Inhibitor V inhibits ALK5, disrupting FHL-2-mediated TGF-β signaling. This inhibition hampers FHL-2 involvement in cellular processes regulated by TGF-β, such as inflammation and immune response modulation. | ||||||
EW-7197 | 1352608-82-2 | sc-507465 | 5 mg | $345.00 | ||
EW-7197 is a selective inhibitor of TGF-β receptor type I (ALK5). FHL-2 is associated with TGF-β pathways, and EW-7197 inhibits ALK5, disrupting FHL-2-mediated TGF-β signaling. This inhibition interferes with FHL-2 involvement in cellular processes regulated by TGF-β, such as cell migration and invasion. EW-7197 provides a tool to investigate the specific impact of ALK5 inhibition on FHL-2 function and cellular dynamics. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $70.00 $198.00 | 18 | |
SB216763 is a selective inhibitor of glycogen synthase kinase 3β (GSK-3β). FHL-2 interacts with GSK-3β, and SB216763 inhibits GSK-3β, modulating FHL-2-mediated pathways. This inhibition affects FHL-2 involvement in cellular processes regulated by GSK-3β, such as cell proliferation and apoptosis. SB216763 serves as a tool to investigate the specific impact of GSK-3β inhibition on FHL-2 function and cellular dynamics. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $153.00 $520.00 | 4 | |
CHIR-99021 is a selective inhibitor of glycogen synthase kinase 3 (GSK-3). FHL-2 interacts with GSK-3, and CHIR-99021 inhibits GSK-3, disrupting FHL-2-mediated pathways. This inhibition affects FHL-2 involvement in cellular processes regulated by GSK-3, such as cell adhesion and migration. CHIR-99021 provides a tool to investigate the specific impact of GSK-3 inhibition on FHL-2 function and cellular dynamics. | ||||||